Priaxon and GSK agree collaboration
To develop drug discovery approaches to address protein-protein-interactions with small molecules
Priaxon, an emerging pharmaceutical company based in Germany, is to work with GlaxoSmithKline (GSK) to develop small molecule modulators of protein-protein-interactions.
The two companies have signed an agreement following a successful pilot project. Financial details and therapeutics areas have not been revealed.
Priaxon will provide its proprietary small molecule drug discovery expertise, which is particularly suited to investigating the modulation of protein-protein interactions (PPIs). PPIs play an important role in many cell signalling pathways and cell-surface receptor-ligand interactions that become dysregulated in disease states.
The two companies will identify and advance candidates from hits to leads for pre-clinical development, with the long-term aim of developing and commercialising them.